Cooperation Agreement for Palm Oil Research and Development

Aug.29.2023
Cooperation Agreement for Palm Oil Research and Development
Huabao shares announce research collaboration with Malaysian Palm Oil Board and Bunge Loders Croklaan for palm oil-related projects.

Recently, Huabao Group announced on its official website that it has signed a three-party research project cooperation agreement with Malaysian Palm Oil Board's wholly-owned subsidiary, Malaysian Palm Oil Technology Development (Shanghai) Co., Ltd., and Bangi Gordess (Xiamen) Oil and Fat Technology Co., Ltd. The collaboration aims to conduct related technical research and product development using palm oil as the raw material.


PORTSIM, a subsidiary of the Malaysian Palm Oil Board (MPOB), is a branch located in Shanghai, China. Established in 2005, PORTSIM aims to develop, expand, and promote the Malaysian palm oil market in China, while providing technical support and consultancy services to relevant companies. MPOB, a statutory body under the Malaysian government, is primarily responsible for promoting and formulating national goals, policies, and priorities in the palm oil industry in Malaysia.


Bunge Loders Croklaan is a sustainable specialty plant oils and fats producer and supplier in the food manufacturing industry. The company operates the global B2B edible oil business under the brand Bunge (NYSE: BG). Its products are widely used in baking, confectionery, cooking, and infant nutrition.


According to reports, the palm oil industry serves as a foundation of Malaysia's economy, making it the world's second largest palm oil producer after Indonesia. The two countries collectively account for over 80% of global palm oil production, with China emerging as the largest palm oil importing nation worldwide. Palm oil and its derivatives find wide applications in various sectors including food, non-food, and animal feed industries. Due to its extensive usage and high volumes of production, the oil palm crop offers promising investment returns in terms of scientific research and technological advancements.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Exclusive: Glas says FDA-authorized G2 vape includes age-gating technology
Glas has confirmed to 2Firsts that its G2 device, which received a FDA Marketing Granted Order (MGO), incorporates age-gating technology. Based on currently public information, this means the FDA has granted an MGO to the first ENDS product confirmed to incorporate age-gating technology, validating 2Firsts’ earlier inference.
Mar.17
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Bulgaria’s Disposable Vape Ban Receives Formal Approval From the European Commission
Bulgaria’s Disposable Vape Ban Receives Formal Approval From the European Commission
The European Commission has formally published its decision approving Bulgarian legislation banning the placing on the market, offering and sale of disposable e-cigarettes.
Mar.17 by 2FIRSTS.ai